Table 2.

Results of the multivariate Cox regression analyses of Siglec‐15 per clinically important and DDR molecules subgroups.

Siglec‐15 stratified by group	Subgroups	PFS	DSS
Lymph node status	Positive	HR 0.668, 95% CI 0.425–1.048, p = 0.079	HR 0.622, 95% CI 0.368–1.051, p = 0.076
	Negative	HR 0.257, 95% CI 0.090–0.740, p = 0.012	HR 0.173, 95% CI 0.040–0.743, p = 0.018
Differentiation (grade)	Well and moderate	HR 0.556, 95% CI 0.340–0.909, p = 0.019	HR 0.529, 95% CI 0.298–0.939, p = 0.030
	Poor	HR 0.600, 95% CI 0.282–1.278, p = 0.186	HR 0.491, 95% CI 0.234–1.467, p = 0.253
AJCC stage	I–II	HR 0.645, 95% CI 0.406–1.023, p = 0.062	HR 0.494, 95% CI 0.277–0.879, p = 0.017
	III–IV	HR 0.491, 95% CI 0.203–1.186, p = 0.114	HR 0.716, 95% CI 0.297–1.730, p = 0.459
p53 status	Wild type	HR 0.454, 95% CI 0.193–1.070, p = 0.071	HR 0.244, 95% CI 0.080–0.749, p = 0.014
	Mutant	HR 0.625, 95% CI 0.392–1.096, p = 0.054	HR 0.680, 95% CI 0.396–1.169, p = 0.163
BRCA1	Low	HR 0.642, 95% CI 0.409–1.006, p = 0.053	HR 0.703, 95% CI 0.425–1.165, p = 0.171
	High	HR 0.215, 95% CI 0.052–0.888, p = 0.034	HR 0.046, 95% CI 0.005–0.429, p = 0.007
BRCA2	Low	HR 0.565, 95% CI 0.330–0.967, p = 0.037	HR 0.519, 95% CI 0.280–0.962, p = 0.037
	High	HR 0.664, 95% CI 0.353–1.248, p = 0.204	HR 0.718, 95% CI 0.329–1.571, p = 0.407